Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 May 16;17(1):332.
doi: 10.1186/s12885-017-3286-5.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Aleksandar Sekulic  1 , Michael R Migden  2 , Nicole Basset-Seguin  3 , Claus Garbe  4 , Anja Gesierich  5 , Christopher D Lao  6 , Chris Miller  7 , Laurent Mortier  8 , Dedee F Murrell  9 , Omid Hamid  10 , Jorge F Quevedo  11 , Jeannie Hou  12 , Edward McKenna  12 , Natalie Dimier  13 , Sarah Williams  13 , Dirk Schadendorf  14 , Axel Hauschild  15 ; ERIVANCE BCC Investigators
Affiliations
Clinical Trial

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Aleksandar Sekulic et al. BMC Cancer. .

Erratum in

Abstract

Background: In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration-approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic basal cell carcinoma (mBCC) and locally advanced BCC (laBCC), respectively. ORRs by investigator review were 45% (mBCC) and 60% (laBCC). Herein, we present long-term safety and final investigator-assessed efficacy results in patients with mBCC or laBCC.

Methods: One hundred four patients with measurable advanced BCC received oral vismodegib 150 mg once daily until disease progression or intolerable toxicity. The primary end point was IRF-assessed ORR. Secondary end points included ORR, duration of response (DOR), progression-free survival, overall survival (OS), and safety.

Results: At data cutoff (39 months after completion of accrual), 8 patients were receiving the study drug (69 patients in survival follow-up). Investigator-assessed ORR was 48.5% in the mBCC group (all partial responses) and 60.3% in the laBCC group (20 patients had complete response and 18 patients had partial response). ORRs were comparable across patient subgroups, including aggressive histologic subtypes (eg, infiltrative BCC). Median DOR was 14.8 months (mBCC) and 26.2 months (laBCC). Median OS was 33.4 months in the mBCC cohort and not estimable in the laBCC cohort. Adverse events remained consistent with clinical experience. Thirty-three deaths (31.7%) were reported; none were related to vismodegib.

Conclusions: This long-term update of the ERIVANCE BCC trial demonstrated durability of response, efficacy across patient subgroups, and manageable long-term safety of vismodegib in patients with advanced BCC.

Trial registration: This study was registered prospectively with Clinicaltrials.gov , number NCT00833417 on January 30, 2009.

Keywords: Basal cell carcinoma (BCC); Efficacy; Long-term; Safety; Vismodegib.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Swimlane plot of time to response, treatment duration, and duration of follow-up for efficacy-evaluable patients who achieved response in the mBCC cohort (a) and the laBCC cohort (b). laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma
Fig. 2
Fig. 2
Kaplan–Meier plots of DOR (a), PFS (b), and OS (c) by investigator assessment. DOR, duration of response; laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma; OR, overall survival; PFS, progression-free survival
See this image and copyright information in PMC

References

    1. Macha MA, Batra SK, Ganti AK. Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma. Cancer Manag Res. 2013;5:197–203. - PMC - PubMed
    1. Wu S, Han J, Li W-Q, Li T, Qureshi AA. Basal-cell carcinoma incidence and associated risk factors in US women and men. Am J Epidemiol. 2013;178:890–897. doi: 10.1093/aje/kwt073. - DOI - PMC - PubMed
    1. Lucas R, McMichael T, Smith W, Armstrong B. World Health Organization: Solar ultraviolet radiation: global burden of disease from solar ultraviolet radiation. Environmental Burden of Disease Series, No. 13. Geneva, Switzerland, World Health Organization, 2006. http://www.who.int/uv/health/solaruvradfull_180706.pdf.
    1. Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013;24:218–223. - PubMed
    1. Varga E, Korom I, Raskó Z, et al. Neglected basal cell carcinomas in the 21st century. J Skin Cancer. 2011;2011:392151. doi: 10.1155/2011/392151. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data